The ruling keeps Lilly's comparative advertising in market while its obesity franchise battles Novo Nordisk on multiple fronts.

Expanded use of the talazoparib-enzalutamide pair moves the regimen into earlier lines of prostate cancer treatment.

The order adds trade risk to drug supply chains already under pressure from pricing and manufacturing policy.

The company is positioning its mRNA cancer vaccine franchise as a growth driver beyond its COVID business.

The results show a modest efficacy gain alongside safety signals that will shape the drug's path forward.

Local pricing pressure is intensifying competition in the fast-growing Korean GLP-1 market.

The disclosure adds a safety question to BMS's push into autoimmune uses of CAR-T therapy.

The readout supports the biotech's bid to bring an oral GLP-1 into late-stage development.

A rolling filing could add a cardiomyopathy treatment to the small set of Duchenne therapies under review.

The cuts leave the cell therapy developer seeking a buyer or partner after patient deaths in a Phase IIa study.

The results offer a read on demand for clinical research and data services across the drug development industry.

The case highlights how narrowly India's price controls reach, with most medicines outside the regulated list.

The margin cap on oncology trade channels is the latest step in India's effort to lower cancer treatment costs.

The narrow vote could widen access to compounded peptides, a market that has drawn scrutiny over unapproved copies.

The category is spreading into adjacent markets for nutrition, aesthetics and post-treatment care.

The trial targets a common side effect that can limit patients' ability to stay on GLP-1 therapies.

Amgen is among the large-cap entrants trying to differentiate in a market dominated by Lilly and Novo.

The clearances allow the biotech to test a single drug across two autoimmune blood disorders in two countries.